Form 8-K - Current report:
SEC Accession No. 0001104659-24-100239
Filing Date
2024-09-16
Accepted
2024-09-16 16:36:41
Documents
16
Period of Report
2024-09-16
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2424130d1_8k.htm   iXBRL 8-K 64066
2 EXHIBIT 3.1 tm2424130d1_ex3-1.htm EX-3.1 6128
3 EXHIBIT 10.5 tm2424130d1_ex10-5.htm EX-10.5 4865
4 EXHIBIT 10.10 tm2424130d1_ex10-10.htm EX-10.10 5862
  Complete submission text file 0001104659-24-100239.txt   267074

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA bcli-20240916.xsd EX-101.SCH 3036
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE bcli-20240916_lab.xml EX-101.LAB 34240
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE bcli-20240916_pre.xml EX-101.PRE 22373
18 EXTRACTED XBRL INSTANCE DOCUMENT tm2424130d1_8k_htm.xml XML 3808
Mailing Address 1325 AVENUE OF AMERICAS 28TH FLOOR NEW YORK NY 10019
Business Address 1325 AVENUE OF AMERICAS 28TH FLOOR NEW YORK NY 10019 201-488-0460
BRAINSTORM CELL THERAPEUTICS INC. (Filer) CIK: 0001137883 (see all company filings)

EIN.: 207273918 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36641 | Film No.: 241301557
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)